DEVELOPMENT OF SYSTEMIC INSECTICIDES FOR PESTS OF ANIMALS IN THE UNITED STATES1

The first encouraging results in the search for systemic insecticides were obtained in 1944 by Lindquist and his co-workers (53), who found that bed bugs, Cimex lectularius Linnaeus and C. hemipterus (Fabricius), died after feeding on rabbits treated orally with DDT or pyrethrins. In 1946, Knipling and associates (48) treated rabbits with oral and intravenous dosages of insecticides,and reported that rabbits tolerated treatments of lindane and 2 -pivalyl-I,3-indandione at rates that were lethal to mosquitoes, Aedes aegypti (Linnaeus), and human body lice, Pediculus humanus humanus Linnaeus when feeding on the rabbits. These findings, made at the Orlando, Florida, laboratory of the United States Department of Agriculture in conjunction with wartime research on the development of military insecticides, justified the initiation of a project on animal systemic insecticides at the Kerrville, Texas, Livestock Insects Laboratory. Since that date, en­tomologists at Kerrville have worked intensively, screening candidate ma­terials in the laboratory and conducting small-scale field tests with promising compounds. Concurrent toxicological observations have been made by co­ operating veterinarians of the Animal Disease and Parasite Research Divi­sion, and analyses of residues of insecticides in meat and milk have been made by cooperating chemists of the Pesticide Chemicals Research Branch of the Entomology Research Division. A description of steps in the development of the first practical systemic insecticide by the cooperative effort of entomologists, veterinarians, and chemists, both in the U. S. Department of Agriculture and from other or­ganizations and industry, is presented below

Portal vein embolization using a Histoacryl/Lipiodol mixture before right liver resection

Purpose: The purpose of this retrospective study was to evaluate the efficacy and safety of percutaneous transhepatic portal vein embolization (PVE) of the right liver lobe using Histoacryl/Lipiodol mixture to induce contralateral liver hypertrophy before right-sided (or extended right-sided) hepatectomy in patients with primarily unresectable liver tumors. Methods: Twenty-one patients (9 females and 12 males) underwent PVE due to an insufficient future liver remnant; 17 showed liver metastases and 4 suffered from biliary cancer. Imaging was performed prior to and 4 weeks after PVE. Surgery was scheduled for 1 week after a CT or MRI control. The primary study end point was technical success, defined as complete angiographical occlusion of the portal vein. The secondary study end point was evaluation of liver hypertrophy by CT and MRI volumetry and transfer to operability. Results: In all the patients, PVE could be performed with a with a Histoacryl/Lipiodol mixture (n = 20) or a Histoacryl/ Lipiodol mixture with microcoils (n = 1). No procedure-related complications occurred. The volume of the left liver lobe increased significantly (p < 0.0001) by 28% from a mean of 549 ml to 709 ml. Eighteen of twenty-one patients (85.7%) could be transferred to surgery, and the intended resection could be performed as planned in 13/18 (72.3%) patients. Conclusion: Preoperative right-sided PVE using a Histoacryl/Lipiodol mixture is a safe technique and achieves a sufficient hypertrophy of the future liver remnant in the left liver lobe

Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial

Background: Liver Transplantation (LT) is treatment of choice for patients with hepatocellular carcinoma (HCC) within MILAN Criteria. Tumour progression and subsequent dropout from waiting list have significant impact on the survival. Transarterial chemoembolization (TACE) controls tumour growth in the treated HCC nodule, however, the risk of tumour development in the untreated liver is increased by simultaneous release of neo-angiogenic factors. Due to its anti-angiogenic effects, Sorafenib delays the progression of HCC. Aim of this study was to determine whether combination of TACE and Sorafenib improves tumour control in HCC patients on waiting list for LT. Methods: Fifty patients were randomly assigned on a 1:1 ratio in double-blinded fashion at four centers in Germany and treated with TACE plus either Sorafenib (n = 24) or placebo (n = 26). The end of treatment was development of progressive disease according to mRECIST criteria or LT. The primary endpoint of the trial was the Time-to-Progression (TTP). Other efficacy endpoints were Tumour Response, Progression-free Survival (PFS), and Time-to-LT (TTLT). Results: The median time of treatment was 125 days with Sorafenib and 171 days with the placebo. Fourteen patients (seven from each group) developed tumour progression during the course of the study period. The Hazard Ratio of TTP was 1.106 (95% CI: 0.387, 3.162). The results of the Objective Response Rate, Disease Control Rate, PFS, and TTLT were comparable in both groups. The incidence of AEs was comparable in the placebo group (n = 23, 92%) and in the Sorafenib group (n = 23, 96%). Twelve patients (50%) on Sorafenib and four patients (16%) on placebo experienced severe treatment-related AEs. Conclusion: The TTP is similar after neo-adjuvant treatment with TACE and Sorafenib before LT compared to TACE and placebo. The Tumour Response, PFS, and TTLT were comparable. The safety profile of the Sorafenib group was similar to that of the placebo group. Trial registration: ISRCTN2408179

Specific CT 3D rendering of the treatment zone after Irreversible Electroporation (IRE) in a pig liver model: the “Chebyshev Center Concept” to define the maximum treatable tumor size

Background: Size and shape of the treatment zone after Irreversible electroporation (IRE) can be difficult to depict due to the use of multiple applicators with complex spatial configuration. Exact geometrical definition of the treatment zone, however, is mandatory for acute treatment control since incomplete tumor coverage results in limited oncological outcome. In this study, the “Chebyshev Center Concept” was introduced for CT 3d rendering to assess size and position of the maximum treatable tumor at a specific safety margin. Methods: In seven pig livers, three different IRE protocols were applied to create treatment zones of different size and shape: Protocol 1 (n = 5 IREs), Protocol 2 (n = 5 IREs), and Protocol 3 (n = 5 IREs). Contrast-enhanced CT was used to assess the treatment zones. Technique A consisted of a semi-automated software prototype for CT 3d rendering with the “Chebyshev Center Concept” implemented (the “Chebyshev Center” is the center of the largest inscribed sphere within the treatment zone) with automated definition of parameters for size, shape and position. Technique B consisted of standard CT 3d analysis with manual definition of the same parameters but position. Results: For Protocol 1 and 2, short diameter of the treatment zone and diameter of the largest inscribed sphere within the treatment zone were not significantly different between Technique A and B. For Protocol 3, short diameter of the treatment zone and diameter of the largest inscribed sphere within the treatment zone were significantly smaller for Technique A compared with Technique B (41.1 ± 13.1 mm versus 53.8 ± 1.1 mm and 39.0 ± 8.4 mm versus 53.8 ± 1.1 mm; p &lt; 0.05 and p &lt; 0.01). For Protocol 1, 2 and 3, sphericity of the treatment zone was significantly larger for Technique A compared with B. Conclusions: Regarding size and shape of the treatment zone after IRE, CT 3d rendering with the “Chebyshev Center Concept” implemented provides significantly different results compared with standard CT 3d analysis. Since the latter overestimates the size of the treatment zone, the “Chebyshev Center Concept” could be used for a more objective acute treatment control

Septic rupture of the ascending aorta after aortocoronary bypass surgery

We describe an exceptional case of non-fatal septic rupture of the ascending aorta in a patient with sternal dehiscence, deep sternal wound infection (DSWI) and pleural empyema after aortocoronary bypass surgery. Routine follow-up computed tomography (CT) detected a mediastinal pseudoaneurysm originating from the ascending aorta. Thereby, massive and irregular sternal bone defects and contrast-enhancing mediastinal soft tissue suggest osteomyelitis and highly-active and aggressive DSWI as initial triggers. Urgent thoracotomy 1 day later included ascending aorta reconstruction, total sternum resection and broad wound debridement. Follow-up CT 1 year later showed a regular postoperative result in a fully recovered patient

Proceedings of the Tenth Annual Beef Cattle Short Course.

91 p

Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib® versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation – HeiLivCa [ISRCTN24081794]

<p>Abstract</p> <p>Background</p> <p>Disease progression of hepatocellular cancer (HCC) in patients eligible for liver transplantation (LTx) occurs in up to 50% of patients, resulting in withdrawal from the LTx waiting list. Transarterial chemoembolization (TACE) is used as bridging therapy with highly variable response rates. The oral multikinase inhibitor sorafenib significantly increases overall survival and time-to-progression in patients with advanced hepatocellular cancer.</p> <p>Design</p> <p>The HeiLivCa study is a double-blinded, controlled, prospective, randomized multi-centre phase III trial. Patients in study arm A will be treated with transarterial chemoembolization plus sorafenib 400 mg bid. Patients in study arm B will be treated with transarterial chemoembolization plus placebo. A total of 208 patients with histologically confirmed hepatocellular carcinoma or HCC diagnosed according to EASL criteria will be enrolled. An interim patients' analysis will be performed after 60 events. Evaluation of time-to-progression as primary endpoint (TTP) will be performed at 120 events. Secondary endpoints are number of patients reaching LTx, disease control rates, OS, progression free survival, quality of live, toxicity and safety.</p> <p>Discussion</p> <p>As TACE is the most widely used primary treatment of HCC before LTx and sorafenib is the only proven effective systemic treatment for advanced HCC there is a strong rational to combine both treatment modalities. This study is designed to reveal potential superiority of the combined TACE plus sorafenib treatment over TACE alone and explore a new neo-adjuvant treatment concept in HCC before LTx.</p

Радиографический метод контроля сварных швов трубопроводов

Обнаружение дефектов сварных соединений является одной из основных задач неразрушающего контроля, применяемого для диагностики технического состояния трубопроводов различного назначения. Среди методов неразрушающего контроля широкое распространение получил радиографический метод. Для обработки изображений, полученных радиографическим методом, и обнаружения дефектов сварки, используются различные алгоритмы. Одним из перспективных алгоритмов обработки изображений является алгоритм, основанный на методе нейронной сети.Detection of defects in welded joints is one of the main tasks of non-destructive testing used for diagnostics of the technical condition of pipelines for various purposes. Among the methods of nondestructive testing, the radiographic method is widely used. For processing images obtained by radiographic method, and the detection of welding defects, various algorithms are used. One of the promising algorithms for image processing is an algorithm based on the neural network method

DEVELOPMENT OF SYSTEMIC INSECTICIDES FOR PESTS OF ANIMALS IN THE UNITED STATES1

The first encouraging results in the search for systemic insecticides were obtained in 1944 by Lindquist and his co-workers (53), who found that bed bugs, Cimex lectularius Linnaeus and C. hemipterus (Fabricius), died after feeding on rabbits treated orally with DDT or pyrethrins. In 1946, Knipling and associates (48) treated rabbits with oral and intravenous dosages of insecticides,and reported that rabbits tolerated treatments of lindane and 2 -pivalyl-I,3-indandione at rates that were lethal to mosquitoes, Aedes aegypti (Linnaeus), and human body lice, Pediculus humanus humanus Linnaeus when feeding on the rabbits. These findings, made at the Orlando, Florida, laboratory of the United States Department of Agriculture in conjunction with wartime research on the development of military insecticides, justified the initiation of a project on animal systemic insecticides at the Kerrville, Texas, Livestock Insects Laboratory. Since that date, en­tomologists at Kerrville have worked intensively, screening candidate ma­terials in the laboratory and conducting small-scale field tests with promising compounds. Concurrent toxicological observations have been made by co­ operating veterinarians of the Animal Disease and Parasite Research Divi­sion, and analyses of residues of insecticides in meat and milk have been made by cooperating chemists of the Pesticide Chemicals Research Branch of the Entomology Research Division. A description of steps in the development of the first practical systemic insecticide by the cooperative effort of entomologists, veterinarians, and chemists, both in the U. S. Department of Agriculture and from other or­ganizations and industry, is presented below